Navigation Links
Resverlogix Board of Directors Update
Date:11/26/2008

    Provides shareholders with an update on internal policy and clinical
    developments

TSX Exchange Symbol: RVX

CALGARY, Nov. 26 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that the previously announced internal blackout trading restriction of April 21, 2008 has been lifted. All previously announced discussions regarding regional and global partnerships are actively ongoing and should the Board or Management become aware of any new insider information the normal blackout procedures will be reinstated.

Resverlogix is also pleased to announce that the second arm of the previously announced Phase 1b/2a study has been successfully completed and the third arm will commence shortly.

About RVX-208

RVX-208, a first in class novel small molecule therapeutic that facilitates endogenous Apolipoprotein A-I (ApoA-I) production, is positioned to be one of the most promising emerging drugs in the treatment of atherosclerosis and vascular disorders such as Alzheimer's disease, vascular dementia, stroke, and Peripheral Artery Disease (PAD). ApoA-I, the critical cardioprotective protein of high-density lipoprotein (HDL) represent the bodies natural defense system against atherosclerosis by mediating reverse cholesterol transport (RCT), the transport of peripheral cholesterol including that of the vessel wall to the liver for processing. To the Company's knowledge RVX-208 is the only novel small molecule that is specifically designed to increase ApoA-I production and thereby raise Prebeta-HDL levels thus enhancing HDL functionality to augment reverse cholesterol transport (RCT) from vascular beds.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
2. Resverlogix Announces Closing of Debt Redemption
3. Resverlogix Eliminates Sixty Percent of Remaining Debt
4. Resverlogix Issues a Management Statement
5. Resverlogix Board of Directors Update
6. Resverlogix Notice of Conference Call & Webcast
7. Jan Gray Joins Resverlogix Board of Directors
8. Resverlogixs Lead Drug Featured in Key Scientific Publication
9. Industry Leaders Select Resverlogixs RVX-208
10. /C O R R E C T I O N from Source -- Resverlogix Corp./
11. Resverlogix Notice of Conference Call & Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... Oct. 10, 2017 SomaGenics announced the receipt ... to develop RealSeq®-SC (Single Cell), expected to be the ... RNAs (including microRNAs) from single cells using NGS methods. ... need to accelerate development of approaches to analyze the ... "New techniques for measuring levels of mRNAs in ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program ... honoring scientists who have made outstanding contributions to analytical chemistry and ... 2018, the world’s leading conference and exposition for laboratory science, which will be ...
(Date:10/9/2017)... ... 09, 2017 , ... The award-winning American Farmer television series will feature 3 ... airs Tuesdays at 8:30aET on RFD-TV. , With global population estimates nearing ten ... to continue to feed a growing nation. At the same time, many of our ...
(Date:10/9/2017)... Arizona (PRWEB) , ... October 09, 2017 , ... ... Kindred, a four-tiered line of medical marijuana products targeting the needs of consumers ... and packaging of Kindred takes place in Phoenix, Arizona. , As operators of ...
Breaking Biology Technology:
(Date:5/6/2017)... , May 5, 2017 RAM ... announced a new breakthrough in biometric authentication based ... quantum mechanical properties to perform biometric authentication. These new ... semiconductor material created by Ram Group and its ... entertainment, transportation, supply chains and security. Ram Group ...
(Date:4/17/2017)... 17, 2017 NXT-ID, Inc. (NASDAQ: NXTD ... filing of its 2016 Annual Report on Form 10-K on Thursday ... ... available in the Investor Relations section of the Company,s website at ... website at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... , Apr. 11, 2017 Research and ... Market 2017-2021" report to their offering. ... The global eye tracking market to grow at a ... report, Global Eye Tracking Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
Breaking Biology News(10 mins):